Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Ovarian Cancer
Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer
FDA Approvals, News & Updates
,
Ovarian Cancer
December 2022, Vol 13, No 6
On
November 14, 2022
, the FDA accelerated the approval of mirvetuximab soravtansine-gynx (Elahere; ImmunoGen), an intravenous folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after 1 to 3 previous systemic treatments, regardless of previous use of bevacizumab (Avastin). Patients should be identified for treatment with mirvetuximab soravtansine by an FDA-approved test.
Read Article
Maintenance with PARP Inhibitors Extends Survival in Patients with Advanced Ovarian Cancer
By
Wayne Kuznar
Ovarian Cancer
June 2021, Vol 12, No 3
Despite improvements in the treatment of advanced ovarian cancer, less than half of newly diagnosed patients survive longer than 5 years, and relapse rates remain high. At the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer, experts presented updated results from 2 phase 3 clinical trials showing the benefit of the poly (ADP-ribose) polymerase (PARP) inhibitors olaparib (Lynparza) and niraparib (Zejula) as maintenance therapy in women with advanced or recurrent disease.
Read Article
Olaparib Extends Survival by >1 Year in Patients with Ovarian Cancer and BRCA Mutation, Ushering in Personalized Medicine in This Malignancy
By
Wayne Kuznar
Ovarian Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
With follow-up of more than 5 years, women with relapsed platinum-sensitive ovarian cancer and a
BRCA
mutation who participated in the multicenter phase 3 SOLO2 clinical trial lived more than 1 year longer when randomized to maintenance therapy with the poly (ADP- ribose) polymerase (PARP) inhibitor olaparib (Lynparza) compared with placebo, according to data released at the ASCO 2020 virtual annual meeting.
Read Article
October 28, 2019 – Oncology News & Updates
FDA Approvals, News & Updates
,
In the News
,
Ovarian Cancer
,
Solid Tumors
Web Exclusives
Read Article
Adding PARP Inhibitor to Immune Checkpoint Blockade Improves Responses in Ovarian Cancer with BRCA Mutations
By
Wayne Kuznar
Ovarian Cancer
June 2019, Vol 10, No 3
San Francisco, CA—Ovarian cancers with
BRCA
mutations are less immunogenic than other DNA repair–deficient tumors. Targeting the DNA damage response using PARP inhibitors may help to improve the modest responses of ovarian cancer seen with single-agent immune checkpoint inhibitors, said Panagiotis A. Konstantinopoulos, MD, PhD, Director of Translational Research, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Read Article
Can Immunotherapy Work in Ovarian Cancer?
By
Wayne Kuznar
Immunotherapy
,
Ovarian Cancer
,
Personalized Medicine
June 2019, Vol 10, No 3
San Francisco, CA—Patients with ovarian cancer can respond to immunotherapy, but rationally designed synergistic combinations will be necessary to enhance upfront efficacy and to sustain durability, said Daniel J. Powell Jr, PhD, Scientific Director of Immunotherapy, Division of Gynecologic Oncology, Center for Cellular Immunotherapy, University of Pennsylvania, Philadelphia, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Read Article
Psychological Support vs Standard of Care Following Chemotherapy for Ovarian Cancer
ESMO 2018
,
Ovarian Cancer
,
ESMO
Conference Correspondent
Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support.
Read Article
Phase 3 Trial of Lurbinectedin vs Pegylated Liposomal Doxorubicin or Topotecan in Platinum-Resistant Ovarian Cancer Patients
ESMO 2018
,
Ovarian Cancer
,
ESMO
Conference Correspondent
Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer.
Read Article
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
ESMO 2018
,
Ovarian Cancer
,
ESMO
Conference Correspondent
Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer.
Read Article
Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and Stable Disease
ESMO 2018
,
Ovarian Cancer
,
ESMO
Conference Correspondent
Olaparib maintenance may prolong progression-free survival in patients, regardless of the number of previous platinum-based chemotherapies.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma